Who are Irinotecan/Cetuximab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FluCAM [Fludara + Campath], Chemotherapy and antibodies.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irinotecan-cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Irinotecan/Cetuximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irinotecan/Cetuximab (Irinotecan/Cetuximab) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy and monoclonal antibody. Area: Oncology.

phase 3 Combination chemotherapy and monoclonal antibody Topoisomerase I (irinotecan); EGFR (cetuximab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Irinotecan/Cetuximab (Irinotecan/Cetuximab) — Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente. Irinotecan inhibits topoisomerase I to damage cancer cell DNA, while cetuximab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy sensitivity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Irinotecan/Cetuximab TARGET	Irinotecan/Cetuximab	Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente	phase 3	Combination chemotherapy and monoclonal antibody	Topoisomerase I (irinotecan); EGFR (cetuximab)
FluCAM [Fludara + Campath]	FluCAM [Fludara + Campath]	Genzyme, a Sanofi Company	phase 3	Combination chemotherapy and monoclonal antibody	Ribonucleotide reductase / DNA polymerase (fludarabine); CD52 (alemtuzumab)
Chemotherapy and antibodies	Chemotherapy and antibodies	St. Jude Children's Research Hospital	phase 3	Combination chemotherapy and monoclonal antibody therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy and monoclonal antibody class)

Genzyme, a Sanofi Company · 1 drug in this class
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Irinotecan/Cetuximab — Competitive Intelligence Brief. https://druglandscape.com/ci/irinotecan-cetuximab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab